Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowBiomet said it plans to appeal the decision within NASDAQ, and that the stock is expected to stay listed until the appeals panel makes a decision.
NASDAQ notified Biomet on Jan. 11 of the failure to file, the company said.
The company said Dec. 18 it had agreed to be bought by a group of private equity firms in a deal valued at $10.9 billion. The consortium includes Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co. and TPG.
Biomet co-founder and CEO Dane Miller resigned in March after several quarters of flagging financial performance. However, he is expected to be an investor in the buyout.
Biomet’s headquarters will remain in Warsaw.
Please enable JavaScript to view this content.
